Modifié le
A study to assess the efficacy and safety of dazodalibep in Sjögren's disease
A study to assess the efficacy and safety of the CD40 ligand antagonist dazodalibep in Sjögren's disease
Modifié le
📣 10 Open Positions for different locations for the European project SIGNATURE!
The Doctoral Network SIGNATURE is hiring 10 PhD candidates in Europe
Modifié le
New article in Nature Review in Rheumatology
Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases
Modifié le
15th International Symposium on Sjögren's Syndrome
The 15th international symposium on Sjögren's Syndrome will take place in Rome from 7 to 10 September 2022.
Modifié le
New study to investigate ianalumab and its mechanism of efficacy in Sjögren's patients
New study to investigate the ianalumab monoclonal antibody and its mechanism of efficacy in Sjögren's patients
Modifié le
Transfer Technology Prize: Olivier Mignen and his group awarded
Dr. Olivier Mignen and his team have been awarded the prize of 'Transfer of Technology' by Ouest Valorisation.
Modifié le
Machine learning identifies a common signature for anti-SSA/Ro60 antibody expression across autoimmune diseases
Autoantibodies are markers of autoimmune diseases. The most frequently observed is the anti-SSA/Ro autoantibody. It is observed in Gougerot-Sjögren syndrome, systemic lupus erythematosus, undifferentiated connectivites but also sometimes in rheumatoid arthritis and scleroderma. Using artificial intelligence approaches on multi-omics data [...]
Modifié le
Successful application to MSCA Doctoral Networks 2021 call
LBAI will be involved in a new European project after the successful application of the SIGNATURE proposal to the MSCA Doctoral Networks 2021 call.